Mereo BioPharma Correlations
MREO Stock | USD 2.52 0.17 6.32% |
The current 90-days correlation between Mereo BioPharma Group and Terns Pharmaceuticals is 0.15 (i.e., Average diversification). A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Mereo BioPharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Mereo BioPharma Group moves in either direction, the perfectly negatively correlated security will move in the opposite direction.
Mereo BioPharma Correlation With Market
Significant diversification
The correlation between Mereo BioPharma Group and DJI is 0.04 (i.e., Significant diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Mereo BioPharma Group and DJI in the same portfolio, assuming nothing else is changed.
Mereo |
Moving together with Mereo Stock
0.61 | TERN | Terns Pharmaceuticals | PairCorr |
0.79 | CTMX | CytomX Therapeutics | PairCorr |
0.81 | EMBC | Embecta Corp | PairCorr |
Moving against Mereo Stock
0.32 | OPT | Opthea Earnings Call Tomorrow | PairCorr |
0.45 | ELV | Elevance Health | PairCorr |
0.5 | WPM | Wheaton Precious Metals | PairCorr |
0.47 | OBI | Ondine Biomedical | PairCorr |
0.47 | EC | Ecopetrol SA ADR Earnings Call Tomorrow | PairCorr |
0.42 | KO | Coca Cola Aggressive Push | PairCorr |
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Mereo Stock performing well and Mereo BioPharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Mereo BioPharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
TERN | 3.21 | (0.67) | 0.00 | 0.53 | 0.00 | 5.17 | 26.61 | |||
PDSB | 4.19 | (0.79) | 0.00 | (0.53) | 0.00 | 9.21 | 26.16 | |||
INZY | 4.08 | (1.20) | 0.00 | 0.79 | 0.00 | 7.72 | 38.13 | |||
HOOK | 3.38 | (0.61) | 0.00 | 0.42 | 0.00 | 7.00 | 32.80 | |||
DAWN | 1.83 | (0.13) | 0.00 | (0.30) | 0.00 | 3.92 | 10.17 | |||
XFOR | 7.37 | 0.88 | 0.10 | (0.48) | 7.11 | 26.42 | 68.45 | |||
ABOS | 2.87 | (0.72) | 0.00 | (0.62) | 0.00 | 6.70 | 15.46 | |||
AMLX | 3.28 | (0.99) | 0.00 | (8.69) | 0.00 | 5.85 | 16.76 | |||
EFTR | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
ELEV | 4.77 | (0.03) | 0.00 | 0.31 | 0.00 | 10.77 | 40.61 |
Mereo BioPharma Corporate Management
Christine CPA | Chief Officer | Profile | |
Bo Kara | Senior CMC | Profile | |
Fiona Bor | Head Property | Profile | |
Jackie Parkin | Therapy Endocrinology | Profile | |
MBBS MD | CoFounder Strategy | Profile | |
John Lewicki | Chief Officer | Profile |